Bevacizumab (Avastin ®) is a humanized monoclonal antibody that inhibits vascular endothelial growth factor A and is commonly used to treat various cancers, including colorectal, lung, breast, kidney, and glioblastomas.
As a typical IgG1 antibody, Bevacizumab is comprised of a tetramer of two heavy and two light chains with one N-glycosylation site per heavy chain.

Bevacizumab comes off-patent in 2018 (extended expiry) and already several companies are developing biosimilar versions of Avastin.

Protagen has experience in the analysis of different variants of Avastin originators and biosimilars.

To support the analytical development of Avastin biosimilars or biobetters, Protagen has set up an analysis program in accordance with ICH Q6B guidelines, including method setup, validation of customer-specific methods, and release testing. This package includes protein quantification, characterizing the protein primary structure, analysis of N- glycosylation and protein modifications.

Specific BioAssay provided by a strategic partner:

  • Target: VEGF Assay type: Neutralization/proliferation Assay


Your contact for Bevacizumab at Protagen Protein Services GmbH

Martin-Blueggel 150x100px

Martin Blüggel

Chief Executive Officer (CEO)
Our business development team will be happy to assist you with your project.

Phone: +49 (0) 231 9742-6100